Wang Ying, Ma Haoyuan, Zhang Bowen, Li Sainan, Lu Beijia, Qi Yingcheng, Liu Tingting, Wang Hua, Kang Xiaohong, Liang Yinming, Kong Eryan, Cao Liu, Zhou Binhui
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, PR China; Institute of Psychiatry and Neuroscience of Xinxiang Medical University, Xinxiang, Henan, PR China.
Laboratory of Genetic Regulators in the Immune System, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, PR China.
J Adv Res. 2024 Dec 26. doi: 10.1016/j.jare.2024.12.041.
Liver pathologies represent a spectrum of conditions ranging from fatty liver to the aggressive hepatocellular carcinoma (HCC), as well as parasitic infections, which collectively pose substantial global health challenges. S-palmitoylation (commonly referred to as palmitoylation), a post-translational modification (PTM) characterized by the covalent linkage of a 16-carbon palmitic acid (PA) chain to specific cysteine residues on target proteins, plays a pivotal role in diverse cellular functions and is intimately associated with the liver's physiological and pathological states.
This study aims to elucidate how protein palmitoylation affects liver disease pathophysiology and evaluates its potential as a target for diagnostic and therapeutic interventions.
Recent studies have identified the key role of protein palmitoylation in regulating the development and progression of liver diseases. This review summarizes the intricate mechanisms by which protein palmitoylation modulates the pathophysiological processes of liver diseases and explores the potential of targeting protein palmitoylation modifications or the enzymes regulating this modification as prospective diagnostic biomarkers and therapeutic targets.
肝脏疾病涵盖了从脂肪肝到侵袭性肝细胞癌（HCC）等一系列病症，以及寄生虫感染，这些疾病共同构成了重大的全球健康挑战。S-棕榈酰化（通常称为棕榈酰化）是一种翻译后修饰（PTM），其特征是16碳棕榈酸（PA）链与靶蛋白上的特定半胱氨酸残基共价连接，在多种细胞功能中起关键作用，并与肝脏的生理和病理状态密切相关。
本研究旨在阐明蛋白质棕榈酰化如何影响肝脏疾病的病理生理学，并评估其作为诊断和治疗干预靶点的潜力。
最近的研究已经确定了蛋白质棕榈酰化在调节肝脏疾病发生和发展中的关键作用。本综述总结了蛋白质棕榈酰化调节肝脏疾病病理生理过程的复杂机制，并探讨了将蛋白质棕榈酰化修饰或调节这种修饰的酶作为潜在诊断生物标志物和治疗靶点的可能性。
